High-dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer

There is high-quality evidence that high-dose chemotherapy improves the likelihood of event-free survival at three years and at any stage of follow-up, but there was little or no difference between the groups in the incidence of second cancers at four to nine years.

Abstract

There is high-quality evidence of increased treatment-related mortality and little or no increase in survival by using high-dose chemotherapy with autograft for women with early poor prognosis breast cancer.